Recludix Pharma

Executive Summary

Recludix Pharma is a private biotechnology company based in San Diego, founded in 2020, with a focus on discovering and developing novel therapeutics for inflammatory diseases and oncology. The company's proprietary platform targets SH2 domains, which are critical regulators of protein location and activity in cellular signaling pathways. Dysregulation of SH2 domain-mediated signaling is implicated in many inflammatory and oncologic conditions, and Recludix aims to unlock new therapeutic possibilities by modulating these targets. Although the company is early-stage and has not disclosed specific pipeline details or financing rounds, its innovative approach to a well-validated but underexploited target class positions it as a potential player in the immunology and oncology space. The company remains private, with no publicly available information on clinical candidates, valuation, or employee count, indicating a preclinical or early discovery stage. Despite the lack of public data, the scientific rationale behind SH2 domain targeting is strong, with several successful drugs (e.g., kinase inhibitors) having emerged from related signaling pathway modulation. Recludix's success will depend on its ability to translate platform capabilities into a lead candidate, secure funding, and navigate competitive landscapes.

Upcoming Catalysts (preview)

• TBDIND filing for lead SH2 domain inhibitor program60% success
• TBDSeries A or B financing round announcement70% success
• TBDPublication of preclinical proof-of-concept data in a peer-reviewed journal50% success